Summary of the clinical outcomes of the cases of sclerosing epithelioid fibrosarcoma reported in the literature
| Series/Case report | Patients with follow up | Duration of follow up | No evidence of disease (%; duration) | Recurrence (%; time from Dx) | Metastasis (%; time from Dx) | Death (%; time from Dx) |
|---|---|---|---|---|---|---|
| AWD, alive with disease; Dx, diagnosis; NA, not available. | ||||||
| Meis-Kindblom et al (1995)1 | 16 | 13–207 months | 6/16 (37%; 13–204 months) | 8/15 (53%; 28–132 months) | 6/14 (43%; 56–168 months) | 4/16 (25%; 37–164 months) |
| Reid et al (1996)2 | 1 | 96 months (AWD) | 0 | 0 | 1 (60 months) | 0 |
| Christensen et al (1997)3 | NA | NA | NA | NA | NA | NA |
| Eyden et al (1998)4 | 4 | 4–84 months | 2/4 (50%; 4–36 months) | 2/4 (50%; 10–24 months) | 1/4 (25%; not stated) | 1/4 (25%; 84 months) |
| Gisselsson et al (1998)5 | 1 | 24 months (AWD) | 0 | 1 (24 months) | 0 | 0 |
| Donner et al (2000)6 | 1 | 14 months | 1 (14 months) | 0 | 0 | 0 |
| Bilsky et al (2000)7 | 3 | 12–59 months | 0/3 (0%) | 2/3 (67%; 10–13 months) | 3/3 (100%; 0–36 months) | 1/3 (33%; 59 months) |
| Arya et al (2001)8 | 1 | 48 months | 1 (48 months) | 0 | 0 | 0 |
| Antonescu et al (2001)9 | 14 | 13–124 months | 1/14 (7%; 13 months) | 7/14 (50%; 2–46 months) | 12/14 (86%; 0–102 months) | 8/14 (57%; 13–86 months) |
| Hanson et al (2001)10 | 1 | 12 months | 0 | 0 | 1 (1.5 months) | 1 (12 months) |
| Jiao et al (2002)11 | 1 | 20 months | 1 (20 months) | 0 | 0 | 0 |
| Abdulkader et al (2002)12 | 1 | 60 months | 0 | 0 | 1 (36 months) | 0 |
| Cumulative data | 44 | 4–207 months | 12/43 (28%; 13–204 months) | 20/42 (48%; 2–132 months) | 25/42 (60%; 0–168 months) | 15/43 (35%; 12–164 months) |